Mycoplasma pneumoniae

Revision as of 18:12, 12 December 2011 by Vanbot (talk | contribs) (Robot: Changing Category:DiseaseState to Category:Disease)
Jump to navigation Jump to search
Mycoplasma pneumoniae

WikiDoc Resources for Mycoplasma pneumoniae

Articles

Most recent articles on Mycoplasma pneumoniae

Most cited articles on Mycoplasma pneumoniae

Review articles on Mycoplasma pneumoniae

Articles on Mycoplasma pneumoniae in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mycoplasma pneumoniae

Images of Mycoplasma pneumoniae

Photos of Mycoplasma pneumoniae

Podcasts & MP3s on Mycoplasma pneumoniae

Videos on Mycoplasma pneumoniae

Evidence Based Medicine

Cochrane Collaboration on Mycoplasma pneumoniae

Bandolier on Mycoplasma pneumoniae

TRIP on Mycoplasma pneumoniae

Clinical Trials

Ongoing Trials on Mycoplasma pneumoniae at Clinical Trials.gov

Trial results on Mycoplasma pneumoniae

Clinical Trials on Mycoplasma pneumoniae at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mycoplasma pneumoniae

NICE Guidance on Mycoplasma pneumoniae

NHS PRODIGY Guidance

FDA on Mycoplasma pneumoniae

CDC on Mycoplasma pneumoniae

Books

Books on Mycoplasma pneumoniae

News

Mycoplasma pneumoniae in the news

Be alerted to news on Mycoplasma pneumoniae

News trends on Mycoplasma pneumoniae

Commentary

Blogs on Mycoplasma pneumoniae

Definitions

Definitions of Mycoplasma pneumoniae

Patient Resources / Community

Patient resources on Mycoplasma pneumoniae

Discussion groups on Mycoplasma pneumoniae

Patient Handouts on Mycoplasma pneumoniae

Directions to Hospitals Treating Mycoplasma pneumoniae

Risk calculators and risk factors for Mycoplasma pneumoniae

Healthcare Provider Resources

Symptoms of Mycoplasma pneumoniae

Causes & Risk Factors for Mycoplasma pneumoniae

Diagnostic studies for Mycoplasma pneumoniae

Treatment of Mycoplasma pneumoniae

Continuing Medical Education (CME)

CME Programs on Mycoplasma pneumoniae

International

Mycoplasma pneumoniae en Espanol

Mycoplasma pneumoniae en Francais

Business

Mycoplasma pneumoniae in the Marketplace

Patents on Mycoplasma pneumoniae

Experimental / Informatics

List of terms related to Mycoplasma pneumoniae

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Epidemiology and Demographics

Each year an estimated 2 million cases and 100,000 pneumonia-related hospitalizations occur in the United States.

Trends

Unknown. However, with improved diagnostic testing, more cases may be identified.

Risk Factors

Persons of all ages are at risk but rarely children less than 5 years old. It is the leading cause of pneumonia in school-age children and young adults. Outbreaks can occur especially in crowded military and institutional (e.g., college) settings. Outbreaks in these settings can last several months.

Pathophysiology & Etiology

Etiologic Agent:

Mycoplasma pneumoniae, a small bacterium. This class of organisms lack a peptidoglycan cell wall present on all other firmicute bacteria. Instead, it has a cell membrane which incorporates sterol compounds, similar to eukaryotic cells. It obtains these sterols from the host serum, allowing it to retain a simple structure. Lacking a cell wall, these organisms are resistant to the effects of penicillins and other beta-lactam antibiotics, which act by disrupting the bacterial cell wall.

M. pneumoniae has one of the smallest genomes known, with 816 kilobase pairs (kbs). Its genome and proteome has been fully characterized. It uses some unique genetic code, making its code more similar to mitochondria than to other bacteria. Thus it is said that Mycoplasma pneumoniae has a degenerate genome. It lacks the cellular machinery for making many essential compounds, including new purines and pyrimidines. It also has no tri-carboxylic acid cycle and an incomplete electron transport chain. Because of this, it is an obligate parasite.

Transmission:

Person-to-person transmission by contact with respiratory secretions. Once attached to the mucosa of a host organism, M. pneumonia extracts nutrients, grows and reproduces by binary fission. Attachment sites include the upper and lower respiratory tract, causing pharyngitis, bronchitis and pneumonia. The infection caused by this bacterium is called atypical pneumonia because of its protracted course and lack of sputum production and wealth of extra-pulmonary symptoms. Chronic mycoplasma infections have been implicated in the pathogenesis of rheumatoid arthritis and other rheumatological diseases.

Diagnosis

M. pneumoniae infections can be differentiated from other types of pneumonia by the relatively slow progression of symptoms, a positive blood test for cold-hemagglutinins in 50-70% of patients after 10 days of infection, lack of bacteria in a gram stained sputum sample, and a lack of growth on blood agar.

History and Symptoms

Majority with upper respiratory tract infections with fever, cough, malaise, and headache. May lead to tracheobronchitis with fever and nonproductive cough: radiologically confirmed pneumonia develops in 5-10% of cases; rare extrapulmonary syndromes, including cardiologic, neurologic, and dermatologic findings.

Risk Stratification and Prognosis

Persistent cough is common during convalescence; other sequelae are rare. Fatal cases are reported occasionally, primarily among the elderly and persons with sickle-cell disease.

References

Acknowledgements

The content on this page was first contributed by: C. Michael Gibson, M.S., M.D. Template:SIB

Template:WH Template:WS